DCGI

FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc

Molnupiravir Not Included in India’s COVID-19 Clinical Management Protocol

The experts of the task force cited safety concerns...

FILE PHOTO: COVID-19 vaccination in New Delhi

DCGI Okays Covaxin For Young Adults Aged 12-18 Years, With Some Conditions

Payal Banerjee 25/12/2021

It is the second vaccine to receive the regulator's...

volodymyr-hryshchenko-m1Hq4ibP9rc-unsplash

The Dangerous Irrationality of How Indian Regulators Classify Substandard Drugs

Priyanka Pulla 13/10/2021

While regulators deal with substandard drugs in a way...

Bharat_Biotech_Covaxin_Bangalore_BESTpedia

Expert Panel Recommends Emergency-Use Okay for Covaxin in 2-18 Age Group

Payal Banerjee 12/10/2021

The recommendations have been forwarded to the Drugs Controller...

FILE PHOTO: File labelled "Sputnik V coronavirus disease (COVID-19) vaccine

Sputnik V Second Dose Shortage To Delay India’s Full Rollout: Dr Reddy’s

Krishna N. Das 12/07/2021

Daily vaccinations hit a national record of 9.2 million...

FILE PHOTO: Workers take care of the shipment of Russia's Sputnik V vaccine at the airport, in Caracas

India Refuses Emergency Use License for One-Dose Sputnik

The Subject Expert Committee of the CDSCO said there...

download (1)

DCGI Expert Panel Recommends Against SII’s Proposal for Covovax Trial on Children

Payal Banerjee 01/07/2021

The Subject Expert Committee said the Pune-based company should...